Guixé Muntet, Sergi; Zhu, Chang-Peng; Xie, Wei-Fen; Gracia Sancho, Jorge (2020). Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & therapeutics, 215, p. 107626. Elsevier 10.1016/j.pharmthera.2020.107626
Text
1-s2.0-S016372582030156X-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB) |
Portal hypertension (PH) is the most common non-neoplastic complication of chronic liver disease, determining clinical complications that lead to death or liver transplantation. PH results from increased resistance to portal blood flow through the cirrhotic liver, which is due to hepatic fibrosis and microcirculatory dysfunction. The present review focuses on the pathophysiology of fibrosis and PH, describes currently used treatments, and critically discusses potential therapeutic options.